AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability ProfileBenzinga • 06/02/21
AC Immune Provides Update on Alzheimer's Disease Vaccine Candidates Targeting Pathological Amyloid-BetaGlobeNewsWire • 06/02/21
AC Immune to Highlight First-in-Class Alzheimer's Disease Vaccine Programs at Upcoming Investor ConferencesGlobeNewsWire • 05/20/21
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/28/21
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of DirectorsGlobeNewsWire • 03/31/21
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative DiseaseGlobeNewsWire • 03/31/21
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and PipelineGlobeNewsWire • 03/26/21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D OutlookGlobeNewsWire • 03/23/21
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative DiseasesGlobeNewsWire • 03/09/21
AC Immune's Alzheimer's Vaccine Candidate Elicit Response In Early-Stage Study; Shares RallyBenzinga • 02/11/21
AC Immune's Alzheimer's Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a StudyGlobeNewsWire • 02/11/21
AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson's DiseaseGlobeNewsWire • 02/08/21
AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome PathwayGlobeNewsWire • 01/29/21
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assayGlobeNewsWire • 12/15/20
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of DirectorsGlobeNewsWire • 11/20/20